Recent preclinical studies have shown that DPP-4i can increase viability and proliferation of tumor cells, and accelerates EMT through the CXCL12/CXCR4/mTOR axis both in vitro and in vivo (14, 30). The gene discussed is MTOR; the disease is neoplasm.